Navigation Links
BioElectronics Announces Conference Call to Update Investors on Growth Initiatives
Date:5/15/2008

CEO Andrew Whelan to present Corporate Growth Plan on Tuesday, May 20th

FREDERICK, Md., May 15 /PRNewswire-FirstCall/ -- BioElectronics Corp. (Pink Sheets: BIEL), the maker of the ActiPatch(TM), a drug free anti-inflammatory patch with an embedded battery operated microchip delivering weeks of continuous pulse therapy for a few cents an hour, today announced it will hold a conference call to update investors on the growth initiatives implemented by the company. Andrew Whelan, President and CEO of BioElectronics Corp. will outline the important changes made in 2007 to realign the company for growth and the successes currently being realized both domestically and internationally.

"These are very exciting times for BioElectronics Corporation. During 2007 we made many changes to the organization to realign in preparation for significant revenue growth," commented Mr. Whelan. "These changes are starting to yield dividends in the form of the introduction of many new products, a growing distributor base, and most importantly, strong revenue growth. Please join us next week as we outline the changes we have made to the organization and our exciting growth prospects for 2008 and beyond."

The conference call will be held on Tuesday, May 20, 2008 at 4:15 p.m. (EDT). To access the conference call from within the United States and Canada please dial (800) 610-4500 and enter access code 37321. To access the call from locations outside of the United States and Canada, please dial (702) 851-3339 and enter access code 37321.

About BioElectronics Corporation

BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's Food and Drug Administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class II pulsed electromagnetic medical device as have numerous other international regulatory agencies. Information on ActiPatch and BioElectronics Corporation is available at the following websites:

-- U.S. Consumer http://www.actipatchonline.com

-- Podiatry: http://www.pemfpodiatry.com

-- Plastic Surgery: http://www.plasticsurgeryrelief.com and

http://www.makemeheal.com

-- German orthopedic foot & ankle: http://www.diesfussexperten.de

-- Italy and Switzerland: http://www.actipatch.it

-- Canada: http://www.actipatchpaintherapy.ca

-- Netherlands: http://www.actipatch.de

-- Singapore & Malaysia: http://www.astonixlife.com/

-- BioElectronics Corp: http://www.bioelectronicscorp.com

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Media Contact:

Patricia Baker, The Big Picture Agency LLC

Voice: 413-623-0950 ext. 221, email: pbaker@bigpictureagency.com

Investor Relations Contact:

Joe Noel, Emerging Growth Research LLP

Voice: 925-922-2560, email: jnoel701@emerginggrow.com


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioElectronics Corporation Announces Singapore and Malaysia Sales
2. BioElectronics Corporation Announces Distribution Agreement With TSS Medical of Italy
3. BioElectronics Announces Canadian Retail Product Launch
4. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit
5. BioElectronics Corporation Receives Major Orders From Italian Distributor
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Md. , Feb. 4, 2016  Spherix Incorporated ... to the fostering and monetization of intellectual property, today ... and Uniden in the Northern District of ... moving forward.  Inter Partes Re-examination ... U.S. Patent Office.  The IPR was initiated on only ...
(Date:2/4/2016)... , February 4, 2016 Strasbourg, ... (ABL), Inc. --> Strasbourg, France , ... --> PharmaVentures is pleased to announce that it acted ... biopharmaceutical manufacturing unit in Strasbourg, France , ... --> --> Transgene (Euronext: TNG), ...
(Date:2/3/2016)... , Feb. 3, 2016  Discovery Laboratories, Inc. ... on developing aerosolized KL4 surfactant therapies for respiratory ... has approved an inducement award as a component ... its newly appointed President and Chief Executive Officer.  ... Committee on February 1, 2016 and granted as ...
(Date:2/3/2016)... Feb. 3, 2016 Harvard Apparatus Regenerative ... company developing bioengineered organ implants for life-threatening conditions ... that CEO Jim McGorry , will present ... on Tuesday, February 9, 2016 at 8:00 ... . HART,s presentation will be webcast live ...
Breaking Biology Technology:
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 /PRNewswire/ ... sensor-based diagnostic products, today announced the closing of a $9 ... investors.  Proceeds from the financing will be used to accelerate ... device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has been ...
(Date:1/7/2016)... 2016 This BCC Research report studies the ... and devices, identifying newer markets and exploring the expansion ... biometric devices. Includes forecast from 2015 to 2020. ... and explore the expansion of the present application market ... of biometric technology, determine its current market size, and ...
(Date:1/7/2016)... 7, 2016  A United States District Court in ... in the country to interpret a biometric privacy statute ... forward against the photo website Shutterfly brought by the law ... NORBERG vs. SHUTTERFLY, INC.; and THISLIFE, INC ( ... Shutterfly violates the Illinois Biometric Privacy Act by collecting ...
Breaking Biology News(10 mins):